InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,358.80
(
0.19%
)
Dow Jones
42,124.65
(
0.00%
)
Brent Oil
74.87
(
1.53%
)
Bitcoin
63,496.21
(
0.27%
)
Post# of 160314
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jaybird249

Send PM Follow Ignore
Followers 82
Posts 2822
Boards Moderated 0
Alias Born 05/05/2006

jaybird249

Re: None

Saturday, 04/17/2010 5:38:31 PM

Saturday, April 17, 2010 5:38:31 PM

Post# of 160314
CYCC mentioned with Merck and Pfizer: will be MONSTER Monday:
http://seekingalpha.com/instablog/353981-michael-becker/63734-cyclin-dependent-cancer-confab-preview

At AACR, Cyclacel is introducing a second-generation CDK product candidate, which is currently in investigational new drug [IND]-directed development. The undisclosed molecule is a second generation oral CDK inhibitor with increased potency. Three abstracts related to both seliciclib and the second-generation compound are scheduled for presentation at AACR.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up